ArticleFrontiers in oncology2025
Efficacy and safety of hetrombopag in the treatment of chemotherapy-related thrombocytopenia in solid tumors: a retrospective study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to evaluate the efficacy and safety of hetrombopag in the management of chemotherapy-induced thrombocytopenia (CIT) among patients with solid tumors, utilizing a retrospective cohort study design. Methods: The study population comprised patients experiencing CIT due to chemotherapy for solid tumors, who received treatment at the General Hospital of Northern Theater Command from January 2023 to December 2024. Participants were categorized into four distinct cohorts based on their treatment regimens: the recombinant human thrombopoietin (rhTPO) monotherapy group, the hetrombopag monotherapy group, the combination therapy group (hetrombopag with rhTPO), and the recombinant human interleukin-11 (rhIL-11) monotherapy group. The primary outcomes evaluated included treatment response rate, alterations in platelet count (PLT), time to PLT recovery, differences in PLT counts pre- and post-treatment; secondary outcome measured encompassed rates of platelet transfusion, and incidence of adverse events (AEs). Results: The study included a total of 187 patients, distributed as follows: 64 in the rhTPO group, 37 in the hetrombopag group, 36 in the combination therapy group, and 50 in the rhIL-11 group. The hetrombopag + rhTPO group exhibited a significantly higher treatment response rate (P<0.05) compared to the other three groups. Furthermore, this group showed superior PLT levels on days 7 and 14, a greater increment in PLT post-treatment, and the shortest median time to PLT recovery to ≥100×10 Conclusion: The combination of hetrombopag and rhTPO therapy exhibits superior efficacy compared to monotherapy in the treatment of CIT in patients with solid tumors. This combination therapy is associated with rapid elevation of platelet counts and a shortened recovery period, while maintaining a favorable safety profile. Furthermore, hetrombopag monotherapy has shown efficacy comparable to that of rhTPO and recombinant human interleukin-11 (rhIL-11), thereby supporting its recommendation for clinical use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.